Trial Profile
An Open, Non-randomised, Multi-centre Phase I Study to Assess the Safety and Efficacy of Fluzoparib Given in Combination With Apatinib in Patients With Recurrent Ovarian Cancer or Triple Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Aug 2022
Price :
$35
*
At a glance
- Drugs Fuzuloparib (Primary) ; Rivoceranib (Primary)
- Indications Advanced breast cancer; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Triple negative breast cancer
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 01 Mar 2022 Status changed from active, no longer recruiting to completed.
- 13 Jun 2019 Status changed from recruiting to active, no longer recruiting.